Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.36 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165120 | 0.86 | MAOB (0.41) | CTSCMAOBHRH3 | |
| SCHEMBL6164397 | 0.85 | PTPN1 (0.50) | CTSCMAOBMGLLFFAR1FFAR4 | |
| SCHEMBL6163345 | 0.83 | CA12 (0.46) | MAOBMGLLFFAR1FFAR4ENPP2 | |
| SCHEMBL6162827 | 0.82 | MAOB (0.43) | MAOBMGLLFFAR1FFAR4ENPP2 | |
| SCHEMBL6164962 | 0.82 | MAOB (0.43) | CTSCMAOBMGLLFFAR1FFAR4 | |
| SCHEMBL6166638 | 0.82 | ACLY (0.44) | MAOBMGLLFFAR1FFAR4ENPP2 | |
| SCHEMBL6163347 | 0.82 | TRPM2 (0.48) | MAOBMGLLFFAR1FFAR4 | |
| SCHEMBL6161803 | 0.81 | MGLL (0.41) | CTSCMAOBMGLLNLRP3FFAR1 | |
| SCHEMBL6164514 | 0.81 | MGLL (0.48) | MAOBMGLLFFAR1FFAR4 | |
| SCHEMBL6166379 | 0.81 | MGLL (0.48) | MAOBMGLLFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379516-B1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | disclosed |
| US-6903086-B2 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-06-07 | — | — | US | disclosed |
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | GPBAR1, GABRP, TBXA2R | CTSC 739/4885MAOB 1558/4885MGLL 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.